Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERMAID-2 durvalumab versus placebo in MRD-positive resected NSCLC
MOH_2021-04-11_009881Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab, Placebo and Observation cohort (3 arms). Primary endpoint: Disease-free survival. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2021-04-11_009881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-11_009881.